| Objective response |
14 [64] |
| Complete response |
3 [14] |
| Partial response |
11 [50] |
| Stable disease |
1 [5] |
| Disease progression |
4 [18] |
| Mixed response |
1 [5] |
| Not evaluable |
2 [9] |
| Duration of response, median (mo) |
8.5 |
| Sites of disease progression |
|
| Intracranial |
7 [32] |
| Extracranial (lung, liver, adrenal, bone, nodes, peritoneum) |
6 [27] |
| Both intracranial & extracranial) |
2 [9] |
| Overall median PFS (mo) |
8 |
| Time to intracranial progression |
11 |
| Time to extracranial progression |
2.5 |
| Overall survival from start of crizotinib (mo) |
20 |
